Citations

Clear

1526 citation(s) found for "Sun, Bo".

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
Luskin, Marlise R. , Lee, Ju-Whei, Fernández, Hugo F. , Bennett, John M. , Ketterling, Rhett P. , Levine, Ross L. , Litzow, Mark R. , Paietta, Elisabeth , Patel, Jay P., Racevskis, Janis, Rowe, Jacob M. , Tallman, Martin S. , Sun, Zhuoxin , Luger, Selina M. , Luskin, Marlise R , Lee, Ju‐Whei , Abdel‐Wahab, Omar , Lazarus, Hillard M. , Ketterling, Rhett P

Mayo Clinic

Blood | January 11, 2016 | Volume: 127 | Issue: 12 | Pages: 1551-1558

10.1182/blood-2015-07-657403 | PMID 26755712 Get It

Key Points High-dose daunorubicin benefits AML patients with favorable and intermediate cytogenetics and with FLT3-ITD, NPM1, and DNMT3A mutations. High-dose daunorubicin is required for the favorable impact of the NPM1 mutation in AML.
Hypercholesterolemia Impairs Nonstenotic Kidney Outcomes After Reversal of Experimental Renovascular Hypertension
Eirin, Alfonso , Zhu, Xiang-Yang, Textor, Stephen C., Lerman, Lilach O. , Sun, Dong , Chen, Zhi , Sun, Dong , Chen, Zhi , Lerman, Amir , Eirin, Alfonso

Mayo Clinic

American Journal of Hypertension | January 7, 2016 | Volume: 29 | Issue: 7 | Pages: 853-859

10.1093/ajh/hpv222 | PMID 26739189 Get It

Abstract BACKGROUND Revascularization of a stenotic renal artery improves kidney function only in select patients with renovascular hypertension (HT) secondary to atherosclerosis. However, the effects of reversal of renovascular HT (RRHT) on the nonstenotic kidney are unclear. We hypothesized that concurrent hypercholesterolemia (HC) attenuates nonstenotic kidney recovery. METHODS Female domestic pigs were randomized as Normal, renovascular HT, HT+RRHT, HTC (renovascular HT and HC), and HTC+RHT ( n = 7 each). RRHT or sham was performed after 6 weeks of HT. Nonstenotic renal blood flow, glomerular filtration rate, and injurious pathways were studied 4 weeks later. RESULTS Mean arterial pressure increased similarly in HT and HTC and decreased after RRHT. Oxidative stress increased in HT and HTC kidneys, and decreased in HT+RRHT, but remained elevated in HTC+RRHT. Renal interstitial fibrosis, glomerulosclerosis, and tubular injury were all attenuated in HT+RRHT, but not HTC+RRHT. Endothelin-1 signaling and PGF2α isoprostane levels were elevated in both HTC and HTC+RRHT pigs. CONCLUSIONS RRHT reverses nonstenotic kidney injury in experimental renovascular HT, but concurrent HC blunts regression of kidney injury, possibly due to predominant vasoconstrictors and oxidative stress. These findings reinforce the contribution of the nonstenotic kidney and of prevailing cardiovascular risk factors to irreversibility of kidney dysfunction after revascularization.
Mild cognitive impairment and dementia prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study
Sharrett, Albert Richey, Wruck, Lisa , Windham, B. Gwen , Coker, Laura H., Schneider, Andrea L.C. , Sun, Hengrui, Alonso, Álvaro , Albert, Marilyn S. , Knopman, David S. , Gottesman, Rebecca F. , Sharrett, A. Richey, Coresh, Josef , Mosley, Thomas H. , Alonso, Alvaro , Schneider, Andrea L C , Wruck, Lisa M

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | January 4, 2016 | Volume: 2 | Issue: 1 | Pages: 1-11

10.1016/j.dadm.2015.12.002 | PMID 26949733 Get It

AbstractIntroductionWe examined prevalence of mild cognitive impairment (MCI) and dementia in the Atherosclerosis Risk in Communities (ARIC) Neurocognitive study.MethodsBeginning in June, 2011, we invited all surviving ARIC participants to undergo cognitive, neurologic, and brain imaging assessments to diagnose MCI or dementia and assign an etiology for the cognitive disorder.ResultsOf 10,713 surviving ARIC participants (age range, 69–88 years), we ascertained cognitive diagnoses in 6471 in person, 1966 by telephone interviews (participant or informant), and the remainder by medical record review. The prevalence of dementia was 9.0% and MCI 21%. Alzheimer's disease (AD) was the primary or secondary etiology in 76% of dementia and 75% of MCI participants. Cerebrovascular disease was the primary or secondary etiology in 46% of dementia and 32% of MCI participants.DiscussionMCI and dementia were common among survivors from the original ARIC cohort. Nearly 30% of the ARIC cohort received diagnoses of either dementia or MCI, and for the majority of these individuals, the etiologic basis was attributed to AD.
The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB
Liu, Jieqiong , Mao, Kai, Jiang, Wen , Kim, Betty Y.S. , Liu, Qiang , Jacobs, Lisa K. , Jiang, Shuai , Chen, Kai , Jiang, Wen , Kim, Betty Y S

Mayo Clinic

Oncotarget | December 31, 2015 | Volume: 7 | Issue: 17 | Pages: 24848-24859

10.18632/oncotarget.6664 | PMID 26709538 Get It

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
Wu, Changping , Jin, Xin , Yang, Yinhui , He, Yundong , Ding, Liya , Pan, Yunqian , Yang, H. J. , Chen, Shuai , Jiang, Jingting , Huang, Haojie , Jin, Xin

Mayo Clinic

Oncotarget | December 9, 2015 | Volume: 7 | Issue: 3 | Pages: 3440-3452

10.18632/oncotarget.6497 | PMID 26657505 Get It

The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Zhao, Shuang G. , Evans, Joseph R. , Kothari, Vishal , Sun, Grace Y. , Larm, Ashley, Mondine, Victor, Schaeffer, Edward M. , Ross, Ashley E. , Klein, Eric A. , Den, Robert B. , Dicker, Adam P. , Karnes, R. Jeffrey , Erho, Nicholas , Nguyen, Paul L. , Feng, Felix Y. , Zhao, Shuang G , Davicioni, Elai , Den, Robert B , Klein, Eric A , Dicker, Adam P

Mayo Clinic

Clinical Cancer Research | December 2, 2015 | Volume: 22 | Issue: 7 | Pages: 1777-1786

10.1158/1078-0432.ccr-15-1250 | PMID 26631616 Get It

Abstract Purpose: There is a clear need to improve risk stratification and to identify novel therapeutic targets in aggressive prostate cancer. The goal of this study was to investigate genes with outlier expression with prognostic association in high-risk prostate cancer patients as potential biomarkers and drug targets. Experimental Design: We interrogated microarray gene expression data from prostatectomy samples from 545 high-risk prostate cancer patients with long-term follow-up (mean 13.4 years). Three independent clinical datasets totaling an additional 545 patients were used for validation. Novel prognostic outlier genes were interrogated for impact on oncogenic phenotypes in vitro using siRNA-based knockdown. Association with clinical outcomes and comparison with existing prognostic instruments was assessed with multivariable models using a prognostic outlier score. Results: Analysis of the discovery cohort identified 20 prognostic outlier genes. Three top prognostic outlier genes were novel prostate cancer genes; NVL, SMC4, or SQLE knockdown reduced migration and/or invasion and outlier expression was significantly associated with poor prognosis. Increased prognostic outlier score was significantly associated with poor prognosis independent of standard clinicopathologic variables. Finally, the prognostic outlier score prognostic association is independent of, and adds to existing genomic and clinical tools for prognostication in prostate cancer (Decipher, the cell-cycle progression signature, and CAPRA-S). Conclusions: To our knowledge, this study represents the first unbiased high-throughput investigation of prognostic outlier genes in prostate cancer and demonstrates the potential biomarker and therapeutic importance of this previously unstudied class of cancer genes. Clin Cancer Res; 22(7); 1777–86. ©2015 AACR.
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease
Geyer, Holly L. , Scherber, Robyn M. , Dueck, Amylou C. , Kiladjian, Jean‐Jacques , Xiao, Zhijian , Slot, Stefanie , Zweegman, Sonja , Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández‐Maraver, Dolores , Döhner, Konstanze , Harrison, Claire , Radia, Deepti , Muxí, Pablo , Besses, Carlos , Cervantes, Francisco , Johansson, Peter , Andréasson, Björn , Rambaldi, Alessandro , Barbui, Tiziano , Bonatz, Karin, Reiter, Andreas , Boyer, Françoise, Étienne, Gabriel , Ianotto, Jean‐Christophe , Ranta, Dana, Roy, Lydia , Cahn, Jean‐Yves, Ferrari, Maria Luisa, Birgegård, Gunnar , Xu, Junqing , Zhang, Peihong , Boekhorst, Peter A.W. te , Commandeur, Suzan, Schouten, Harry C. , Pahl, Heike L. , Grießhammer, Martin , Stegelmann, Frank , Lehmann, Thomas , Senyak, Zhenya, Passamonti, Francesco , Samuelsson, Jan , Geyer, Holly, Scherber, Robyn, Hernández-Maraver, Dolores, Johansson, Peter L, Maldonado, Norman, Barosi, Giovanni , Ferrari, Maria L, Xu, Zefeng, Sun, Xiujuan, te Boekhorst, Peter A W, Schouten, Harry, Griesshammer, Martin, Dueck, A. C. , Kosiorek, Heidi , Zweegman, Sonja , Cahn, Jean‐Yves , Maldonado, Norman D. , Gale, Robert Peter , Xu, Zefeng , Zhang, Yue , Sun, Xiujuan , Vannucchi, Alessandro M. , Mesa, Ruben A. , Kiladjian, Jean-Jacques , Rambaldi, Alessandro , Ianotto, Jean-Christophe , Passamonti, Francesco

Mayo Clinic

Journal of Clinical Oncology | November 24, 2015 | Volume: 34 | Issue: 2 | Pages: 151-159

10.1200/jco.2015.62.9337 | PMID 26598745 Get It

Purpose Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, and palpable splenomegaly. We aimed to determine how these features contribute alone and in aggregate to the PV symptom burden. Patients and Methods Through prospective evaluation of 1,334 patients with PV who had characterized symptom burden, we assessed patient demographics, laboratory data, and the presence of splenomegaly by disease feature (ie, known HU use, known phlebotomy requirements, splenomegaly). Results The presence of each feature in itself is associated with a moderately high symptom burden (MPN symptom assessment form [SAF] total symptom score [TSS] range, 27.7 to 29.2) that persists independent of PV risk category. In addition, symptoms incrementally increase in severity with the addition of other features. Patients with PV who had all three features (PV-HUPS) faced the highest total score (MPN-SAF TSS, 32.5) but had similar individual symptom scores to patients with known HU use (PV-HU), known phlebotomy (PV-P), and splenomegaly (PV-S). Conclusion The results of this study suggest that patients with PV who have any one of the features in question (known HU use, known phlebotomy, or splenomegaly) have significant PV-associated symptoms. Furthermore, it demonstrates that many PV symptoms remain severe independent of the number of features present.
Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Prébet, Thomas , Sun, Zhuoxin , Ketterling, Rhett P. , Zeidan, Amer M. , Greenberg, Peter L. , Herman, James G. , Malick, Lisa, Paietta, Elisabeth , Czader, Magdalena , Figueroa, María E. , Gabrilove, Janice , Tallman, Martin S. , Litzow, Mark R. , Gore, Steven D. , intergroup, the Eastern Cooperative Oncology Group and North American Leukemia, Juckett, Mark , Smith, Mitchell R. , Erba, Harry Paul , intergroup, the Eastern Cooperative Oncology Group and North American Leukemia, Prebet, Thomas , Ketterling, Rhett P , Zeidan, Amer M

Mayo Clinic

British Journal of Haematology | November 18, 2015 | Volume: 172 | Issue: 3 | Pages: 384-391

10.1111/bjh.13832 | PMID 26577691 Get It

AbstractTherapy‐related myeloid neoplasms (tMN) are serious late effects of the treatment of cancer with poor response to conventional treatment. Azacitidine (AZA) has been used to treat patients with tMN but current data are retrospective. We present here 47 tMN patients prospectively enrolled as a specific cohort in the E1905 study. TheE1905 study was a randomized phase 2 study (NCT00313586) testing 10 d of AZA (50 mg/m2/d) +/− the histone deacetylase inhibitor entinostat (4 mg/m2/d PO day‐3 and day‐10). A total of 47 patients [29 therapy‐related myelosyspastic syndrome (t‐MDS) and 18 therapy‐related acute myeloid leukaemia (t‐AML)] were recruited to the study. 24 patients were treated with AZA monotherapy and 23 with AZA+entinostat. The median number of administered cycles was 4, significantly higher in patients treated with AZA (6 cycles vs. 3 cycles, P = 0·008). Haematological normalization rates were 46% in monotherapy and 17% in the combination arm. Median overall survivals were 13 and 6 months, respectively. The novel 50 * 10 schedule of azacitidine appears effective, with response rates, when given as single agent, comparable to those for patients with de novo MDS/AML treated on the same protocol. However, the combination of AZA and entinostat was associated with increased toxicity and could not be recommended for treatment of tMN.
High-Throughput Long Noncoding RNA Profiling for Diagnostic and Prognostic Markers in Cancer: Opportunities and Challenges
Sun, Zhifu , Sun, Zhifu

Mayo Clinic

Epigenomics | November 6, 2015 | Volume: 7 | Issue: 7 | Pages: 1075-1078

10.2217/epi.15.69 | PMID 26541179 Get It